Affinity Asset Advisors, LLC Immunovant, Inc. Call Options Transaction History

Affinity Asset Advisors, LLC

6 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 13, 2024	BUY	$27.51 - $27.51 $651,987 - $651,987	23,700 Added 43.65%	78,000 $2.15 Million
Q2 2024 Aug 14, 2024	SELL	$25.1 - $31.61 $2.26 Million - $2.85 Million	-90,100 Reduced 62.4%	54,300 $1.43 Million
Q1 2024 May 14, 2024	BUY	$30.27 - $43.79 $4.37 Million - $6.32 Million	144,400 New	144,400 $4.67 Million
Q4 2021 Feb 11, 2022	SELL	$7.33 - $9.32 $219,900 - $279,600	-30,000 Closed	0 $0
Q2 2021 Aug 13, 2021	SELL	$9.4 - $16.85 $376,000 - $674,000	-40,000 Reduced 57.14%	30,000 $317,000
Q1 2021 May 14, 2021	BUY	$13.08 - $49.6 $915,600 - $3.47 Million	70,000 New	70,000 $1.12 Million

211

66M

2.3M

631K

Ticker IMVT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 129,077,000
Market Cap $3.55B
Description
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of mya...

Get notified when there are updates to the investment portfolio of Affinity Asset Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Affinity Asset Advisors, LLC with notifications on news.